SEC Filing Summary: Disc Medicine, Inc. (IRON)
Business Context and Reporting Period
This Form 8-K, dated July 30, 2026, reports on Disc Medicine, Inc.'s financial results for the second quarter ended June 30, 2026. The filing serves as a current report to announce these results and provide a corporate update, with the detailed press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide data to compare current period performance against prior comparable periods. No specific material changes in financial condition or operations are detailed in the excerpt provided.
Guidance, Outlook, and Risks
Management provided a corporate update alongside the financial results, but the specific content of the outlook, guidance, or risk factors is not detailed in this filing text. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash burn figures.
- Verify the company's cash runway and liquidity position as of June 30, 2026.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the corporate update.
- Check for any new debt financing or equity raises disclosed in the full press release.